Trials / Completed
CompletedNCT00314041
Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants
A Randomized, Double-blind, Controlled, Active Comparator, Phase II Study to Assess the Tolerance and Immunogenicity of Conjugate Meningococcal C (MnCC) Vaccine in Infants When Administered in Conjunction With Primary DTP/Hib Vaccination at 2, 3, and 4 Months of Age.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 240 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 7 Weeks – 10 Weeks
- Healthy volunteers
- Accepted
Summary
Infant phase: To determine the safety of and production of antibodies by a group C meningococcal conjugate vaccine (MnCC), when given at 2, 3, and 4 months of age with routine vaccines. Booster phase: To compare the safety of and production of antibodies by MnCC with and without MMR and to compare the antibody response to that produced by a low dose of plain polysaccharide vaccine as a way of investigating immune memory
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Meningococcal C | |
| BIOLOGICAL | DTP/Hib |
Timeline
- Start date
- 1997-06-01
- Primary completion
- 1998-04-01
- Completion
- 1998-04-01
- First posted
- 2006-04-12
- Last updated
- 2013-02-21
Source: ClinicalTrials.gov record NCT00314041. Inclusion in this directory is not an endorsement.